CRISPR Therapeutics（纳斯达克代码：CRSP）报告其季度每股亏损$(0.44)，优于分析师预期的$(1.13)，超出预期61.06%。与去年同期的每股收益$1.10相比，下降了140%。公司季度销售额为$35.691百万，超出分析师预期的$7.657百万，超出预期366.13%。与去年同期的销售额$201.206百万相比，下降了82.26%。

以上内容来自Benzinga Earnings专栏，原文如下：

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(1.13) by 61.06 percent. This is a 140 percent decrease over earnings of $1.10 per share from the same period last year. The company reported quarterly sales of $35.691 million which beat the analyst consensus estimate of $7.657 million by 366.13 percent. This is a 82.26 percent decrease over sales of $201.206 million the same period last year.